A
IMVT icon

AlphaQuest’s Immunovant IMVT Stock Holding History

AlphaQuest’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,326
Closed -$237K – 974
2025
Q4 		$237K Sell
9,326
-3,578
-28% -$79.8K 0.01% 1362
2025
Q3 		$208K Buy
12,904
+12,010
+1,343% +$194K 0.01% 1382
2025
Q2 		$14.3K Sell
894
-4,806
-84% -$72.7K ﹤0.01% 1827
2025
Q1 		$97.4K Buy
5,700
+5,346
+1,510% +$112K 0.01% 1310
2024
Q4 		$8.77K Buy
354
+342
+2,850% +$9.7K ﹤0.01% 1478
2024
Q3 		$342 Sell
12
-2,598
-100% -$76.6K ﹤0.01% 1773
2024
Q2 		$68.9K Buy
2,610
+1,786
+217% +$50.8K 0.01% 1021
2024
Q1 		$26.6K Buy
824
+823
+82,300% +$30K ﹤0.01% 1004
2023
Q4 		$42 Buy
+1
New +$37 ﹤0.01% 1055

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

AlphaQuest's IMVT Position: Q1 2026 in Review

AlphaQuest sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 9,326 shares — an estimated $237K sold.

AlphaQuest first reported a position in IMVT in Q4 2023 and held it in 9 quarters. The position peaked at $237K in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • AlphaQuest reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 9,326 Immunovant shares in Q1 2026, an estimated $237K.
  • AlphaQuest first reported a position in Immunovant in Q4 2023 and held it in 9 quarters.
  • AlphaQuest's Immunovant position peaked at $237K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.